The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.

Eloralintide

LY3841136 · Eloralintide

C
Animal replicated
Research chemicalAmylin Receptor AgonistAMY1R AgonistPeptide
RouteInjectableGray-market only
C
Evidence grade: Animal replicated

Effect demonstrated in multiple animal studies; human data sparse or extrapolated. Grades summarize evidence quality, not whether a compound is appropriate, legal, or risk-free.

At a glance
What it is
LY3841136 — Selective AMY1R Agonist — Eli Lilly — Phase 3 (2025-2026) — Amylin Receptor Agonist, AMY1R Agonist, Peptide.
Why people use it
Used primarily for weight loss.
What the evidence supports
Eloralintide is in active Phase 3 clinical development as of mid-2026. Unlike cagrilintide (which entered the community research chemical space earlier in its development cycle), eloralintide's Phase 2 completion in August 2025 and Phase 3 initiation in December 2025 make its community availability very limited. A small number of research chemical vendors may carry it as of May 2026, but supply is minimal and quality verification is even more difficult than for more established research chemicals. The synthesis complexity of eloralintide (37 amino acids with a methylene thioacetal bridge and specific lipidation chemistry) is substantially higher than simpler peptides like BPC-157 or TB-500 — the probability of synthesis errors in research chemical production is meaningfully higher. For community users: eloralintide's Phase 3 enrollment creates a realistic opportunity to participate in clinical trials rather than self-administering unverified research chemicals. Phase 3 trials typically compensate participants and provide pharmaceutical-grade product with medical oversight. Searching ClinicalTrials.gov for NCT06230523 follow-on Phase 3 studies is the recommended approach.
If you only read one thing

Eloralintide is the pharmacological hypothesis made flesh: if AMY1R is responsible for amylin's weight-loss-producing satiety effects, and if CTR and AMY3R are responsible for the class liabilities (MTC risk and nausea), then selectively targeting AMY1R should produce a drug with equivalent or superior weight loss and better safety and tolerability. The Phase 2 Lancet (December 2025) provides striking support for the efficacy part: -20.1% weight loss at 9mg in 48 weeks — the highest published figure for an amylin monotherapy, considerably exceeding cagrilintide's -11.5% in its Phase 3. The tolerability data from Phase 2 suggests favorable GI profile relative to non-selective agonists. The MTC question cannot be answered by Phase 2 — it requires long-term Phase 3 human safety data and post-marketing pharmacoepidemiology. Whether the AMY1R selectivity meaningfully de-risks the MTC concern vs cagrilintide's non-selective profile remains to be established. Phase 3 results, expected 2027-2028, will be definitive.

Check interactions →
Published literature
1human RCT0human studies1animal1in vitro

Phase 2 randomized obesity data supports the human-RCT badge; Phase 3 is ongoing and not counted as completed evidence.

Evidence reality check
Human evidence
1 human study
1 randomized; 0 observational.
Preclinical base
2 lab signals
1 animal; 1 in-vitro/mechanistic.
Evidence snapshot
Eloralintide is in active Phase 3 clinical development as of mid-2026. Unlike cagrilintide (which entered the community research chemical space earlier in its development cycle), eloralintide's Phase 2 completion in August 2025 and Phase 3 initiation in December 2025 make its community availability very limited. A small number of research chemical vendors may carry it as of May 2026, but supply is minimal and quality verification is even more difficult than for more established research chemicals. The synthesis complexity of eloralintide (37 amino acids with a methylene thioacetal bridge and specific lipidation chemistry) is substantially higher than simpler peptides like BPC-157 or TB-500 — the probability of synthesis errors in research chemical production is meaningfully higher. For community users: eloralintide's Phase 3 enrollment creates a realistic opportunity to participate in clinical trials rather than self-administering unverified research chemicals. Phase 3 trials typically compensate participants and provide pharmaceutical-grade product with medical oversight. Searching ClinicalTrials.gov for NCT06230523 follow-on Phase 3 studies is the recommended approach.
From the chapter quick-reference block.
Categories
Weight Loss & Metabolic
Properties
✓ Human RCT
Half-life
pharmacokinetics consistent with once-weekly dosing (half-life ~7 days from albumin-bound lipidated structure)
Evidence
CAnimal replicated
The AMY1R Selectivity — The Defining Design Choice
Amylin receptors are heterodimers of the calcitonin receptor (CTR) + one of three RAMP proteins: AMY1R (CTR+RAMP1), AMY2R (CTR+RAMP2), AMY3R (CTR+RAMP3). Cagrilintide (Novo Nordisk) is a non-selective agonist that activates AMY1R, AMY3R, and CTR roughly equivalently. Eloralintide preferentially activates human AMY1R: 12-fold greater potency at AMY1R vs CTR; 11-fold greater vs AMY3R. The clinical significance: AMY1R is primarily responsible for satiety signaling; CTR mediates calcitonin-like effects including the MTC (medullary thyroid carcinoma) rodent signal; reduced CTR engagement theoretically reduces the MTC class concern and may reduce nausea.
Phase 2 Lancet Results (December 2025)
Billings LK et al. The Lancet. Vol 406, Issue 10520, Dec 6, 2025 (published online Nov 6, 2025). NCT06230523. 48-week DBRPC trial; n=263; adults with obesity or overweight + ≥1 comorbidity without T2D; US only. Weight loss by arm: 1mg = -9.5%; 3mg = -12.1%; 6mg = -14.4%; 3-6-9mg escalation = -16.7%; 6-9mg escalation = -18.1%; 9mg = -20.1%; placebo = -0.4%. ALL TREATMENT ARMS MET PRIMARY ENDPOINT. Dose-dependent weight loss from 9.5% to 20.1% vs 0.4% placebo. Well-tolerated; no serious unexpected safety signals.
Phase 3 Status (2025-2026)
Eli Lilly announced Phase 3 initiation immediately after the November 2025 ObesityWeek presentation: 'Lilly will begin enrolling Phase 3 clinical studies for the treatment of obesity next month.' Phase 3 enrollment started December 2025. Phase 3 completion and results: anticipated 2027-2028. Lilly also running Phase 2 combination study with tirzepatide (NCT06603571): eloralintide + tirzepatide in obesity with T2D. No community research chemical or compounded access currently widely available; limited gray-market availability as of May 2026.
Eloralintide vs Cagrilintide — The Key Comparison
Both are long-acting amylin analogues targeting AMY1R for satiety and weight loss. The critical difference: AMY1R selectivity. Eloralintide: AMY1R-selective (12x > CTR); lower conditioned taste avoidance in rats (less nausea signal); Phase 2 Lancet 2025 -20.1% at 9mg. Cagrilintide: non-selective agonist (AMY1R + AMY3R + CTR equally); higher conditioned taste avoidance; Phase 3 REDEFINE 1 cagrilintide monotherapy = -11.5% at 68 weeks. The efficacy comparison is not directly comparable (different Phase and doses) but eloralintide's 20.1% at 48 weeks is markedly higher than cagrilintide's 11.5% at 68 weeks, suggesting AMY1R selectivity may provide superior weight loss as well as better tolerability.
Simple view

Need the deep dive?

The default page keeps the decision layer visible first: summary, routes, evidence, and risks. Open the full report for mechanisms, chapter sections, citations, updates, and print/share controls.

Alternatives

Compare nearby options

Browse this classCompare 4 side by side →
AOD-9604
C
Same class · Peptide

Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.

Cagrilintide
C
Same class · Peptide

Novo Nordisk's Long-Acting Amylin Analogue. The First New Mechanism in Obesity Pharmacology Since GLP-1. Phase 3 REDEFINE 1 (NEJM, June 2025): CagriSema = 22.7% Weight Loss — Among the Highest Ever Reported for Obesity Medication. Cagrilintide Monotherapy = 11.8% at 68 Weeks. Phase 3 Trials Completed. NDA Filing Expected Q1 2026. Not Yet Approved. Community Access Through Research Vendors.

Mazdutide
C
Same class · Peptide

The World's First Approved Dual GCG/GLP-1 Receptor Agonist. NMPA-Approved in China June 2025 for Obesity. Second NMPA Approval September 2025 for T2D. Phase 3 T2D Data Published Back-to-Back in Nature December 2025. Originally Eli Lilly's LY3305677 — Licensed to Innovent Biologics for China Development. No FDA Submission as of Mid-2026. The Drug That Is Simultaneously Approved, Unavailable, and a Research Chemical Depending on Where You Are.

Check interactions